Prognostic value of total lesion glycolysis measured by F-18-FDG PET/CT in patients with locally advanced cervical cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Hong, Jin Hwa | - |
dc.contributor.author | Jung, Un Suk | - |
dc.contributor.author | Min, Kyung Jin | - |
dc.contributor.author | Lee, Jae Kwan | - |
dc.contributor.author | Kim, Sungeun | - |
dc.contributor.author | Eo, Jae Seon | - |
dc.date.accessioned | 2021-09-03T21:19:43Z | - |
dc.date.available | 2021-09-03T21:19:43Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2016-08 | - |
dc.identifier.issn | 0143-3636 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/87882 | - |
dc.description.abstract | AimThe aim of this study was to determine the most relevant parameters of fluorine-18 fluorodeoxyglucose (F-18-FDG) PET/computed tomography (CT) for predicting recurrence in patients with locally advanced cervical cancer.Materials and methodsFifty-six patients diagnosed with International Federation of Gynecology and Obstetrics (FIGO) stage IIB to IVA cervical cancer who underwent F-18-FDG PET/CT before definitive chemoradiotherapy were retrospectively enrolled. Various PET parameters, namely, maximum standardized uptake value, mean standardized uptake value, metabolic tumor volume, and total lesion glycolysis (TLG) of the primary tumor, were analyzed to evaluate the relationship between these PET parameters and recurrence-free survival (RFS). The cut-off values of PET parameters that showed the best trade-off between sensitivity and specificity for RFS were determined by receiver operating characteristic curve analysis.ResultsThe median follow-up was 20 months (range, 6-63 months). Univariate analysis indicated that higher FIGO stage [hazard ratio (HR) 5.606, 95% confidence interval (CI) 1.682-18.68, P=0.005], metabolic tumor volume more than 47.81cm(3) (HR 6.203, 95% CI 1.351-28.481, P=0.019), and TLG more than 215.02 (HR 11.817, 95% CI 1.518-91.963, P=0.018) were associated with RFS. In multivariate analysis, FIGO stage (HR 4.618, 95% CI 1.295-16.463, P=0.018) and TLG more than 215.02 (HR 10.171, 95% CI 1.246-83.044, P=0.030) were independent predictive factors for RFS. Kaplan-Meier curves for RFS indicated that patients with TLG less than or equal to 215.02 showed better RFS (P=0.003).ConclusionPretreatment TLG proved to be an independent prognostic factor for RFS in patients with locally advanced cervical cancer treated by definitive chemoradiotherapy. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | LIPPINCOTT WILLIAMS & WILKINS | - |
dc.subject | STANDARDIZED UPTAKE VALUE | - |
dc.subject | POSITRON-EMISSION-TOMOGRAPHY | - |
dc.subject | METABOLIC TUMOR VOLUME | - |
dc.subject | PELVIC LYMPH-NODES | - |
dc.subject | FLUORODEOXYGLUCOSE UPTAKE | - |
dc.subject | DISEASE | - |
dc.subject | PRETREATMENT | - |
dc.subject | RECURRENCE | - |
dc.subject | CARCINOMA | - |
dc.subject | PREDICTS | - |
dc.title | Prognostic value of total lesion glycolysis measured by F-18-FDG PET/CT in patients with locally advanced cervical cancer | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Hong, Jin Hwa | - |
dc.contributor.affiliatedAuthor | Min, Kyung Jin | - |
dc.contributor.affiliatedAuthor | Lee, Jae Kwan | - |
dc.contributor.affiliatedAuthor | Kim, Sungeun | - |
dc.contributor.affiliatedAuthor | Eo, Jae Seon | - |
dc.identifier.doi | 10.1097/MNM.0000000000000516 | - |
dc.identifier.scopusid | 2-s2.0-84964053103 | - |
dc.identifier.wosid | 000380110500010 | - |
dc.identifier.bibliographicCitation | NUCLEAR MEDICINE COMMUNICATIONS, v.37, no.8, pp.843 - 848 | - |
dc.relation.isPartOf | NUCLEAR MEDICINE COMMUNICATIONS | - |
dc.citation.title | NUCLEAR MEDICINE COMMUNICATIONS | - |
dc.citation.volume | 37 | - |
dc.citation.number | 8 | - |
dc.citation.startPage | 843 | - |
dc.citation.endPage | 848 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Radiology, Nuclear Medicine & Medical Imaging | - |
dc.relation.journalWebOfScienceCategory | Radiology, Nuclear Medicine & Medical Imaging | - |
dc.subject.keywordPlus | STANDARDIZED UPTAKE VALUE | - |
dc.subject.keywordPlus | POSITRON-EMISSION-TOMOGRAPHY | - |
dc.subject.keywordPlus | METABOLIC TUMOR VOLUME | - |
dc.subject.keywordPlus | PELVIC LYMPH-NODES | - |
dc.subject.keywordPlus | FLUORODEOXYGLUCOSE UPTAKE | - |
dc.subject.keywordPlus | DISEASE | - |
dc.subject.keywordPlus | PRETREATMENT | - |
dc.subject.keywordPlus | RECURRENCE | - |
dc.subject.keywordPlus | CARCINOMA | - |
dc.subject.keywordPlus | PREDICTS | - |
dc.subject.keywordAuthor | cervical cancer | - |
dc.subject.keywordAuthor | F-18-FDG PET | - |
dc.subject.keywordAuthor | CT | - |
dc.subject.keywordAuthor | recurrence | - |
dc.subject.keywordAuthor | survival | - |
dc.subject.keywordAuthor | total lesion glycolysis | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.